Is it safe to buy Healthequity stock after plunging 24% after earnings?

on Dec 7, 2021
  • Healthequity shares on Tuesday plunged 24%.
  • The company announced its FQ3 results Monday after markets closed.
  • Healthequity missed analyst expectations on revenue and earnings.

Follow Invezz on Telegram, Twitter, and Google News for instant updates >

On Tuesday, Healthequity Inc. (NASDAQ:HQY) shares declined by 24% after announcing its most recent quarterly results. The company reported its FQ3 revenue and earnings Monday after markets closed, missing the consensus for analyst expectations. Healthequity also issued a full-year 2022 revenue guidance below the consensus Street forecast.

The company posted FQ3 non-GAAP earnings per share of $0.35, in line with expectations. However, its GAAP EPS of -$0.06 missed the average analyst estimate of $0.00, while revenue for the quarter edged slightly higher by 0.3% from the same quarter last year to $179.95 million, missing expectations by $5.49 million.

Healthequity now expects to post full-year 2022 revenue in the range of $750 million to $755 million, below the consensus Street forecast of $762.09 million.

Is Healthequity stock still overvalued?

Copy link to section

From an investment perspective, Healthequity shares trade at a reasonable forward P/E ratio of 25.05, making it an interesting option for value investors.

However, analysts expect its earnings per share to plummet by nearly 80% this year, before bouncing back by 17.86% next year.

Featured Broker

Looking to invest?

Invest and trade CFD stocks, ETFs, digital assets & commodities in minutes with our highest-rated broker.


Therefore, long-term growth investors may opt for alternatives in the market. The stock has now plummeted more than 34% this year, making it an exciting technical buy for short-term investors.

Are you looking for fast-news, hot-tips and market analysis? Sign-up for the Invezz newsletter, today.

Source – TradingView

Technically, Healthequity shares seem to have plunged to complete a downward channel breakout in the intraday chart. As a result, the stock has fallen deep into oversold conditions, creating the perfect opportunity for a technical rebound.

Therefore, investors could target short-term rebound profits at around $48.57, or higher at $54.22, while $36.90 and $31.43 are crucial support zones.


Copy expert traders easily with eToro. Invest in stocks like Tesla & Apple. Instantly trade ETFs like FTSE 100 & S&P 500. Sign-up in minutes.


77% of retail CFD accounts lose money.

Get demo account
USA Health & pharma North America Stock Market